Articles
Neurofilament Light Chain (NfL): What This MS Blood Test Means for Your Care
Published: April 4, 2026
Author: Dr. Achillefs Ntranos MD
If you've been living with multiple sclerosis for any length of time, you know the routine: MRIs, neurological exams, symptom check-ins. These tools have been the backbone of MS monitoring for decades — and they remain essential. But what if a simple blood draw could add another layer of insight into what's happening inside your nervous system, even between MRI scans?
That's the promise of neurofilament light chain testing. You may have heard your neurologist mention "NfL" at a recent appointment, or you may have come across the term while researching MS online. Either way, you're not alone in wanting to understand what this test actually measures, what the results mean, and whether it should be part of your MS care plan.
In my practice, I've been integrating NfL testing into MS management for several years now. It hasn't replaced anything — it's added a new dimension to how I monitor disease activity and evaluate whether a patient's treatment is working. Here's what you need to know.
What Is Neurofilament Light Chain?
Neurofilament light chain (NfL) is a structural protein found inside nerve cells. Think of neurofilaments as the internal scaffolding that gives nerve fibers their shape and supports the transport of signals along the axon — the long cable-like extension of a neuron.
When nerve cells are damaged — whether by inflammation, demyelination, or degeneration — this scaffolding breaks apart and NfL proteins leak out. They first enter the cerebrospinal fluid (the fluid surrounding the brain and spinal cord), and from there, small amounts cross into the bloodstream.
The key insight is straightforward: more nerve damage means more NfL in the blood.
NfL as a smoke detector for nerve damage
Think of NfL like a smoke detector for your nervous system. It doesn't tell you exactly which room the fire is in or what caused it, but it alerts you that something is actively damaging nerves. That early warning can be invaluable for making timely treatment decisions in MS.
For years, NfL could only be measured in cerebrospinal fluid, which required a lumbar puncture. The breakthrough came with ultrasensitive blood tests that can now detect the tiny concentrations of NfL that reach the bloodstream — making routine monitoring practical for the first time.
Why NfL Matters in MS
MRI has been the gold standard for monitoring MS, and it will continue to be. But MRI has blind spots. It captures a snapshot of structural changes — white matter lesions, brain volume, new or enlarging plaques — but it doesn't always reflect everything happening at the cellular level.
NfL fills some of those gaps:
- Subclinical disease activity: NfL can rise even when MRI looks stable, catching nerve damage that hasn't yet produced a visible lesion or a clinical symptom.
- Treatment response: After starting or switching a disease-modifying therapy, NfL levels typically drop if the treatment is effectively reducing neuroinflammation. Persistently elevated levels may signal that the current therapy isn't providing enough protection.
- Progression monitoring: In progressive forms of MS, where relapses may be infrequent but slow nerve degeneration continues, NfL can help quantify the rate of ongoing damage.
- Predicting outcomes: Research consistently shows that higher NfL levels are associated with greater risk of future relapses, new MRI lesions, brain atrophy, and disability worsening.
I've found that NfL is particularly useful for patients who feel like something is off — maybe their fatigue has worsened or their thinking feels slower — but their MRI looks the same as last year. A rising NfL level in that context gives us objective data to act on, rather than taking a wait-and-see approach.
How the NfL Blood Test Works
From a patient's perspective, NfL testing couldn't be simpler. It's a standard blood draw — a single tube, no fasting required, no special preparation. The sample is sent to a specialized laboratory for analysis.
The technology behind the test is what makes it remarkable. Standard blood tests aren't sensitive enough to detect the extremely low concentrations of NfL in serum. This new test relies on highly sensitive molecular detection technology, which can measure proteins at very low concentrations.
Several commercial laboratories now offer NfL testing, and the turnaround time is typically one to two weeks. Your neurologist orders the test, and the results come back as a numerical value reported in picograms per milliliter (pg/mL).
What Your NfL Results Mean
Interpreting NfL results is not as simple as checking whether a number falls above or below a single cutoff. Context matters enormously.
Age-Adjusted Reference Ranges
NfL levels naturally increase with age, even in healthy individuals. A level that's normal for a 65-year-old might be elevated for a 30-year-old. This is why most laboratories and clinicians use age-adjusted percentiles rather than a single universal "normal range." Your result is compared to what's expected for someone your age without neurological disease.
Trends Over Time Matter Most
A single NfL measurement gives you a snapshot. But the real power of this biomarker comes from tracking it over time. In my practice, I establish a baseline NfL level for each patient and then monitor how it changes at subsequent visits.
| NfL Pattern | What It May Suggest | Clinical Implication |
|---|---|---|
| Normal and stable | No significant ongoing nerve damage | Treatment is likely working well; continue current plan |
| Elevated at baseline | Active disease, recent relapse, or inadequate treatment | May warrant therapy escalation or additional workup |
| Decreasing after treatment change | New therapy is reducing nerve damage | Encouraging sign; continue monitoring |
| Rising over time | Increasing disease activity or progression | Discuss therapy adjustment; correlate with MRI and symptoms |
| Isolated spike | Possible recent relapse, infection, or transient cause | Repeat in 3 months; investigate if clinically relevant |
One number does not tell the whole story
Never interpret an NfL result in isolation. A single elevated value could reflect a recent infection, a minor head injury, or a laboratory variation. Your neurologist considers NfL alongside your MRI findings, clinical exam, symptom history, and overall disease trajectory to make informed decisions.
NfL and Treatment Decisions
One of the most practical applications of NfL testing is evaluating whether your disease-modifying therapy is doing its job. The logic is straightforward: effective treatment reduces inflammation, which reduces nerve damage, which lowers NfL.
In my practice, I often check NfL levels before starting a new therapy and then again six to twelve months later. If the NfL drops into a normal age-adjusted range, that's a strong signal that the treatment is working at the biological level — even before the next MRI.
Conversely, if NfL remains elevated or rises despite being on treatment, that's a red flag. It may prompt a conversation about whether to escalate therapy, perhaps moving from a moderate-efficacy treatment to a higher-efficacy option like those discussed in my comparison of Ocrevus vs Kesimpta vs Briumvi.
NfL can also provide reassurance. Some patients worry about switching therapies or wonder if their current medication is truly helping. Seeing their NfL level drop after starting treatment — or remain low and stable over time — offers concrete evidence that the treatment is providing protection, which can be enormously reassuring.
NfL vs MRI: Complementary Tools
NfL testing does not replace MRI. The two tools answer different questions and work best together.
| Feature | NfL Blood Test | Brain MRI |
|---|---|---|
| What it measures | Active nerve damage (protein released from injured axons) | Structural changes (lesions, atrophy, inflammation) |
| Sensitivity to subclinical activity | High — can detect damage before lesions form | Moderate — may miss early or diffuse damage |
| Specificity to MS | Low — elevated in many neurological conditions | High — lesion patterns are characteristic of MS |
| Frequency | Easy to repeat every 6-12 months via blood draw | Typically annual; more frequent if needed |
| Patient burden | Minimal — simple blood draw | Moderate — requires scanner time, contrast, scheduling |
| Best for | Tracking biological disease activity over time | Diagnosing MS, locating lesions, assessing brain volume |
| Limitations | No location information; affected by age and comorbidities | Snapshot in time; may not reflect ongoing cellular damage |
Understanding your MS brain MRI remains essential for diagnosis, meeting the McDonald criteria, and tracking structural changes. NfL adds a biological signal that MRI alone can't provide — a real-time indicator of whether nerve damage is actively occurring.
Limitations of the NfL Test
As excited as I am about NfL testing, it's important to be honest about what it cannot do.
NfL is not specific to MS. Any process that damages nerve cells will raise NfL levels. This includes other neurological conditions, traumatic brain injury, peripheral neuropathies, and even normal aging. An elevated NfL level on its own cannot diagnose MS or confirm a relapse — it must always be interpreted alongside clinical and imaging data.
There is no universal cutoff. Different laboratories may report slightly different reference ranges, and there is not yet a single agreed-upon threshold that separates "definitely active MS" from "stable disease." This is why tracking your individual trend is more meaningful than focusing on any single number.
Age and comorbidities matter. Older patients, patients with diabetes-related neuropathy, or those with concurrent neurological conditions may have baseline NfL levels that are harder to interpret in the MS context.
It's still evolving. While the research supporting NfL in MS is robust and growing, clinical guidelines are still catching up. Not all neurologists routinely order the test, and insurance coverage remains inconsistent. This is changing rapidly, but it's worth noting.
The Future of Blood Biomarkers in MS
NfL is the most established blood biomarker in MS today, but it's just the beginning. Researchers are investigating several other blood-based biomarkers that may provide complementary information:
- Glial fibrillary acidic protein (GFAP): This protein is released from astrocytes (support cells in the brain) and may help distinguish between relapsing and progressive MS mechanisms. Elevated GFAP levels appear to correlate with progressive disease and brain atrophy.
- Serum NfL trending tools: Newer digital platforms allow patients and clinicians to visualize NfL trends over time alongside MRI and clinical data, making it easier to spot concerning patterns early.
- Personalized biomarker panels: The goal is to eventually combine multiple biomarkers — NfL, GFAP, and others still in development — into a comprehensive blood panel that gives a detailed picture of disease activity, progression risk, and treatment response for each individual patient.
I believe we're moving toward an era where a routine blood draw at your MS visit will provide as much actionable information as an MRI. We're not there yet, but NfL has opened the door. The ongoing clinical trials in this field are producing exciting results, and I expect the pace of progress to accelerate.
When to Ask Your Neurologist About NfL Testing
Not every MS patient needs NfL testing right now, but there are several situations where it can be particularly valuable:
- You've recently started or switched a disease-modifying therapy and want an objective measure of whether it's working
- Your MRI looks stable but you feel like your symptoms are worsening — NfL can help determine whether subclinical disease activity might explain the change
- You're deciding between treatment options and want baseline data to compare future results against
- You have progressive MS and want a way to monitor ongoing nerve damage beyond annual MRI
- You're considering participating in a clinical trial and want to understand your current disease activity level
- You're planning a pregnancy and want to confirm disease stability before adjusting medication
- You simply want to be proactive about tracking your disease with every available tool
The conversation starts with your neurologist. If you're being seen at a general neurology practice, your doctor may be less familiar with NfL testing — which is one reason why working with an MS specialist can make a difference. MS specialists tend to integrate newer biomarkers into their practice earlier because they see enough MS patients to recognize the patterns.
If you're in Southern California, I'm happy to discuss whether NfL testing makes sense for your situation during an in-person visit at our Beverly Hills office or through a telehealth consultation. For patients experiencing an MS relapse or those with questions about whether their treatment is providing adequate protection, NfL can be a valuable part of the conversation.
Discuss NfL Testing
Book an appointment with Dr. Ntranos to discuss whether neurofilament light chain testing is right for your MS care.
MS Treatment Options
Learn about disease-modifying therapies and how your neurologist decides when to start or switch treatment.
Understanding Your MS MRI
NfL and MRI work together. Learn what your brain MRI results mean for your MS diagnosis and treatment.
Frequently Asked Questions
What is neurofilament light chain?
Neurofilament light chain (NfL) is a structural protein found inside nerve fibers. When neurons are damaged — whether from inflammation, degeneration, or injury — NfL is released into the cerebrospinal fluid and blood. Measuring NfL levels in blood provides an indirect but sensitive measure of ongoing nerve damage anywhere in the nervous system.
How is the NfL blood test used in MS?
In multiple sclerosis, the NfL blood test helps detect disease activity that may not be visible on MRI, monitor treatment effectiveness over time, identify patients who may need a therapy change, and potentially predict future relapses and disability progression. It complements rather than replaces MRI and clinical examination in MS management.
What do high NfL levels mean?
Elevated NfL levels indicate active nerve damage. In MS, this can signal ongoing inflammation, recent or subclinical relapses, or disease progression. However, NfL is not specific to MS — levels can be elevated in other neurological conditions, after head trauma, or even with normal aging. Your neurologist interprets NfL results in the context of your full clinical picture.
How often should NfL be tested in MS?
There is no universally agreed-upon schedule yet, but many MS specialists check NfL levels at baseline and then every 6 to 12 months. More frequent testing may be appropriate after starting a new therapy, if disease activity is suspected, or during treatment transitions. The goal is to track your individual trend over time rather than rely on a single measurement.
Is the NfL test covered by insurance?
Coverage varies by insurer and plan. The NfL blood test is becoming more widely available as a commercial laboratory test, but it is not yet universally covered by all insurance plans. Some labs offer patient assistance programs. Ask your neurologist's office about coverage and out-of-pocket costs before ordering the test.
Can NfL levels predict MS relapses?
Research shows that rising NfL levels can precede clinical relapses and new MRI lesions, sometimes by several months. While NfL cannot predict exactly when a relapse will occur, consistently elevated or rising levels suggest that the current treatment may not be adequately controlling disease activity, prompting a conversation about therapy adjustment.
This article is for educational purposes
The information in this article is intended to help you have an informed conversation with your neurologist. NfL testing and interpretation should always be done under the guidance of a qualified MS specialist who understands your complete medical history and disease trajectory.
About the Author
Dr. Achillefs Ntranos MD
Board-Certified Neurologist
Achilles Neurology Clinic
Dr. Achillefs Ntranos MD is a board-certified neurologist and MS specialist known for his thorough evaluations and compassionate approach. Originally from Greece, he trained at Johns Hopkins University and Mount Sinai Hospital before founding Achilles Neurology Clinic in Beverly Hills to deliver comprehensive, patient-centered neurological care. He specializes in MS, autoimmune neurology, neuropathy, headaches, and other neurological disorders, blending research-driven insights with personalized treatment plans.